Why Dilogic for Healthcare, Pharma & Life Sciences
Dilogic is the Strategic Principal for healthcare, pharma, and life sciences. We lead the strategy. We direct best-in-class execution. We pre-clear the work in-house. We stay until the results are showing.
Four models. Four gaps.
Global management consultancies deliver macro healthcare strategy as a slide deck and disengage at handover. Channel-thin. Junior-staffed at delivery. Priced for the largest groups and government clients only. In-house pharma compliance is rare in this category.
Healthcare and pharma agency strategy practices bundle strategy with execution because execution is how the network bills. Strategy is the wedge. The most consequential delivery problem — work being shot down by the client's compliance officer — gets re-routed back through their internal team and then back into rework cycles.
In-house C-suite hires take six months to land in a sector where regulatory and clinical context takes a year to learn. One career's pattern. Wrong hire is eighteen months of damage in a sector where reputation is the asset.
Boutique healthcare strategy firms are usually pharma- or biotech-tilted but US-anchored. They ship a smart document and leave. Limited cross-border fluency for MENA → UK / EU corridor work. In-house compliance of this kind is rare.
Each model has a gap. None stays in the room until the results are showing. None pre-clears the work before it leaves the building. Dilogic was built for both gaps.
What the alternatives offer · what they get wrong
Alternative
Offer
Macro healthcare and life-sciences strategy, system transformation, regulatory advisory at policy level, M&A diligence.
Get wrong
Channel-thin. Junior-staffed at delivery. Slide-deliverable. In-house pharma compliance is rare in this category.
Dilogic instead
Channel-deep AND owns execution direction. Senior-led only. In-house pharma compliance review.
Alternative
Offer
Brand strategy, communications, HCP engagement, congress strategy bundled into execution proposals.
Get wrong
Strategy is a wedge to win execution hours. Compliance is external — work routinely gets shot down by client compliance officer.
Dilogic instead
Independent of execution. Compliance pre-clearing happens in-house — output reaches the client's compliance officer already aligned.
Alternative
Offer
Permanent ownership, deep cultural integration over time.
Get wrong
Six-month landing. Single career pattern. $400k–$800k all-in. Wrong hire = 18+ months of damage. Still doesn't solve the pharma compliance bottleneck.
Dilogic instead
Two-week landing. Cross-client pattern recognition. Outcome-priced. Compliance review embedded in the firm.
Alternative
Offer
Sector-deep strategy documents, often pharma- or biotech-specialized.
Get wrong
Mostly US-anchored. Limited MENA fluency. Hand over the doc and leave. In-house compliance spanning provider, pharma, and biotech is rare.
Dilogic instead
Native to MENA + EU corridors. Stays through execution. Directs the network. Pharma compliance under one roof.
What being the Strategic Principal in healthcare means
In healthcare, the bigger picture is non-trivially harder. Service mix interacts with referral economics. Patient experience interacts with regulator scrutiny. Pharma launches interact with payer access decisions. Brand interacts with HCP perception. We hold all of that in one frame, with one senior partner accountable.
Six interlocking practice areas. Senior-only delivery. Region-native fluency across MENA, the UK, and Europe.
Dilogic does not have an in-house creative team. We don't have an in-house media team. That is a feature.
When a strategy needs execution, we go to our network — vetted senior specialists across creative, media, marketing-ops build, brand identity, event production, content production, research, and regulatory advisory. We brief, we QA, we integrate. In pharma and biotech engagements, the QA loop runs through our in-house pharma compliance team before output reaches the client.
A meaningful share of fees is tied to outcomes — patients identified, leakage closed, launches landed, market entered, partnerships signed. We don't hand over and leave.
We sit in the weekly stand-ups with the executors. We are the client when the situation calls for it. The deliverable is the outcome.
The structural advantage no audited competitor has
Most pharma launches lose more time to internal compliance review than to any other workstream. The reason is structural.
The agency or consultancy producing creative, copy, or strategic recommendations is not pharma-trained on compliance. The client's compliance officer is. So work flows out, gets reviewed, gets rejected on issues the producing team did not anticipate, gets sent back, gets revised, gets reviewed again, gets partially rejected, and so on. Three or four cycles is normal. Six is not unusual. Each cycle is a week.
Dilogic resolves this at the firm level. We hire compliance from a pharma background and integrate it into our senior-led delivery model. Output reaches the client's compliance officer already pre-cleared on the issues that would otherwise generate rejection cycles. The client's compliance team reviews work that has already passed an in-house pharma-trained compliance lens.
Fewer rounds. Faster shipping. Less budget burned. Launches land closer to plan.
From the founder
“ I left Google and a generation of communications consultancies because I kept watching brilliant work die in compliance review. The strategy was right. The creative was right. And then the work would not ship, because no one in the room shared the regulatory frame the work was about to enter. Dilogic exists so the room and the regulatory frame are the same room — and the work ships the first time. ”
Omar Y. Sallam
Founder · Dilogic Group
In practice
A senior partner. Compliance-cleared output. The right specialists for your problem from our network. Accountable to the outcome.
FAQ
